FFO
IOVA icon

Fortitude Family Office’s Iovance Biotherapeutics IOVA Stock Holding History

Fortitude Family Office’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254 Sell
61
-161
-73% -$612 ﹤0.01% 2084
2026
Q1 		$779 Buy
+222
New +$710 ﹤0.01% 1579
2025
Q3 		– Sell
-142
Closed -$244 – 2060
2025
Q2 		$244 Buy
+142
New +$353 ﹤0.01% 1942

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Fortitude Family Office's IOVA Position: Q2 2026 in Review

Fortitude Family Office reduced its Iovance Biotherapeutics (IOVA) stake by 73% in Q2 2026, selling an estimated $612 and leaving 61 shares worth $254. The position accounts for ﹤0.01% of the portfolio, ranked #2084.

Fortitude Family Office first reported a position in IOVA in Q2 2025 and has held it in 3 quarters since. The position peaked at $779 in Q1 2026. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Fortitude Family Office held 61 shares of Iovance Biotherapeutics worth $254 as of Q2 2026.
  • Fortitude Family Office sold 161 Iovance Biotherapeutics shares in Q2 2026, an estimated $612.
  • Iovance Biotherapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2084 holding.
  • Fortitude Family Office first reported a position in Iovance Biotherapeutics in Q2 2025 and has held it in 3 quarters since.
  • Fortitude Family Office's Iovance Biotherapeutics position peaked at $779 in Q1 2026.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.